Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease

被引:44
|
作者
Golabi, Pegah [1 ]
Fukui, Natsu [2 ]
Paik, James [1 ]
Sayiner, Mehmet [2 ]
Mishra, Alita [2 ]
Younossi, Zobair M. [1 ,2 ]
机构
[1] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Claude Moore Hlth Educ & Res Bldg,3300 Gallows Rd, Falls Church, VA 22042 USA
[2] Inova Fairfax Hosp, Dept Med, Ctr Liver Dis, Falls Church, VA USA
关键词
CORONARY-HEART-DISEASE; ASSOCIATION; MANAGEMENT; FIBROSIS; GUIDELINES; DIAGNOSIS; EQUATION; COHORT; NAFLD; PANEL;
D O I
10.1002/hep4.1387
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Cardiovascular diseases (CVDs) are the leading cause of mortality in patients with nonalcoholic fatty liver disease (NAFLD). Our aim was to assess the association of atherosclerotic cardiovascular disease (ASCVD) risk scores with overall and cardiac-specific mortality among patients with NAFLD. We used the National Health and Nutrition Examination Survey III with the National Death Index-linked mortality files. NAFLD was defined by ultrasound as presence of steatosis in the absence of secondary causes of liver disease. High risk for CVD was defined as a 10-year ASCVD score >= 7.5%. Hazard ratios (HRs) and population-attributable fractions (PAFs) of high risk for CVD were calculated. Among 1,262 subjects with NAFLD (47.9% men; 41.2% white; mean age, 56.3 years), the prevalence of high risk for CVD was 55.9% and 4.8% had advanced fibrosis. After a median follow-up of 17.7 years, 482 subjects (38.2%) died of overall causes, of whom 382 (79.3%) had a high risk for CVD. The unadjusted overall and cardiac-specific mortality were higher for patients with NAFLD who had a high risk for CVD compared to subjects with NAFLD with a low risk for CVD (57.3% vs. 16.8% for overall mortality; 16.4% vs. 3.5% for cardiovascular mortality). After controlling for risk factors associated with mortality, high risk for CVD was associated with a 42% higher overall mortality rate (adjusted HR [aHR], 1.42; 95% confidence interval [CI], 1.05-1.91) and twice the risk of cardiovascular mortality (aHR, 2.02; 95% CI, 1.12-3.65). Adjusted PAFs were 11.4% for overall mortality and 44.9% for cardiovascular mortality. Conclusion: Among patients with NAFLD, ASCVD score >= 7.5% was associated with a higher risk of overall and cardiac-specific mortality.
引用
收藏
页码:1050 / 1060
页数:11
相关论文
共 50 条
  • [1] ATHEROSCLEROTIC CARDIOVASCULAR DISEASE SCORE IS AN INDEPENDENT PREDICTOR OF MORTALITY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
    Golabi, Pegah
    Sayiner, Mehmet
    Paik, James
    de Avila, Leyla
    Mishra, Alita
    Younossi, Zobair M.
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S1253 - S1253
  • [2] Performance of nonalcoholic fatty liver fibrosis score in estimating atherosclerotic cardiovascular disease risk
    Huang, Ya-Chin
    Huang, Jiun-Chi
    Chien, Hsu-Han
    Lin, Chia-, I
    Chuang, Yun-Shiuan
    Cheng, Han-Yun
    Lin, Wei-Ting
    Lin, Yu-Yin
    Chuang, Hung-Yi
    Wang, Chao-Ling
    Dai, Chia-Yen
    [J]. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2023, 33 (12) : 2479 - 2487
  • [3] LIVER STIFFNESS RELATES TO AN INCREASED RISK FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
    Cicco, S.
    Argeri, S.
    Dalbeni, A.
    Lauletta, G.
    Vacca, A.
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2023, 25
  • [4] Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
    Targher, Giovanni
    Day, Christopher P.
    Bonora, Enzo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (14): : 1341 - 1350
  • [5] CARDIOVASCULAR RISK IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
    Ceasovschih, A.
    Sorodoc, V.
    Lionte, C.
    Statescu, C.
    Sascau, R. A.
    Aursulesei, V. Onofrei
    Haliga, R. E.
    Bologa, C.
    Stoica, A.
    Sirbu, O.
    Coman, A. E.
    Grigorescu, E. -D.
    Petris, O. R.
    Pavel, M.
    Constantin, M.
    Diaconu, A. -D.
    Morarasu, B. C.
    Rusu-Zota, G.
    Profire, B.
    Culis, N.
    Clim, A.
    Sorodoc, L.
    [J]. ATHEROSCLEROSIS, 2023, 379 : S82 - S83
  • [6] Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease
    Ishido, Shun
    Tamaki, Nobuharu
    Takahashi, Yuka
    Uchihara, Naoki
    Suzuki, Keito
    Tanaka, Yuki
    Miyamoto, Haruka
    Yamada, Michiko
    Matsumoto, Hiroaki
    Nobusawa, Tsubasa
    Keitoku, Taisei
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Nakanishi, Hiroyuki
    Kurosaki, Masayuki
    Izumi, Namiki
    [J]. BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [7] Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease
    Shun Ishido
    Nobuharu Tamaki
    Yuka Takahashi
    Naoki Uchihara
    Keito Suzuki
    Yuki Tanaka
    Haruka Miyamoto
    Michiko Yamada
    Hiroaki Matsumoto
    Tsubasa Nobusawa
    Taisei Keitoku
    Kenta Takaura
    Shohei Tanaka
    Chiaki Maeyashiki
    Yutaka Yasui
    Kaoru Tsuchiya
    Hiroyuki Nakanishi
    Masayuki Kurosaki
    Namiki Izumi
    [J]. BMC Gastroenterology, 23
  • [8] Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease
    Tamaki, Nobuharu
    Kurosaki, Masayuki
    Higuchi, Mayu
    Izumi, Namiki
    [J]. HEPATOLOGY RESEARCH, 2021, 51 (11) : 1172 - 1173
  • [9] The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
    Finney, Alexandra C.
    Das, Sandeep
    Kumar, Dhananjay
    McKinney, M. Peyton
    Cai, Bishuang
    Yurdagul, Arif
    Rom, Oren
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [10] Nonalcoholic fatty liver disease and cardiovascular disease risk
    Schindhelm R.K.
    Diamant M.
    Heine R.J.
    [J]. Current Diabetes Reports, 2007, 7 (3) : 181 - 187